Quivy Vincent, De Walque Stephane, Van Lint Carine
University Libre de Bruxelles, Institut de Biologie et de Médecine Moléculaíres, Laboratoire de Virologie Moléculaire, 12, rue des Professeurs Jeener et Brachet 6041 Gosselies, Belgium.
Subcell Biochem. 2007;41:371-96.
Human Immunodeficiency Virus type 1 (HIV-1) infection can now be treated effectively in many patients in the developed world, using combinations of antiretroviral therapeutics, called Highly Active Anti-Retroviral Therapy (HAART). However, despite prolonged treatment with HAART, the persistence of latently HIV-1-infected cellular reservoirs harboring transcriptionally silent but replication-competent proviruses represents the major hurdle to virus eradication. These latently infected cells are a permanent source for virus reactivation and lead to a rebound of the viral load after interruption of HAART. Therefore, a greater understanding of the molecular mechanisms regulating proviral latency and reactivation should lead to rational strategies aimed at purging these cellular reservoirs of HIV-1. This review summarizes our current knowledge and understanding of the elements involved in HIV-1 transcriptional reactivation: (1) the site of integration; (2) the transcription factor NF-kappaB, which is induced by proinflammatory cytokines (such as TNFalpha) and binds to two kappaB sites in the HIV-1 promoter region; (3) the specific remodeling of a single nucleosome (called nuc-1 and located immediately downstream of the HIV-1 transcription start site under latency conditions) upon activation of the HIV-1 promoter; (4) post-translational acetylation of histones and of non-histone proteins (following treatment with deacetylases inhibitors, which induce viral transcription and nuc-1 remodeling); and (5) the viral trans-activator Tat, which promotes transcription by mediating the recruitment to the HIV-1 promoter of histone-modifying enzymes and ATP-dependent chromatin remodeling complexes required for nucleosome disruption and transcriptional processivity. Finally, this review highlights experimental therapies aimed at administrating HIV-1 gene expression activators (such as HDAC inhibitors) combined with an effective HAART in order to reactivate and decrease/eliminate the pool of latently HIV-1-infected cellular reservoirs
在发达国家,使用抗逆转录病毒疗法的组合,即高效抗逆转录病毒疗法(HAART),目前可以有效地治疗许多1型人类免疫缺陷病毒(HIV-1)感染患者。然而,尽管使用HAART进行了长期治疗,但潜伏感染HIV-1的细胞储存库的持续存在,这些储存库中含有转录沉默但具有复制能力的前病毒,这是根除病毒的主要障碍。这些潜伏感染的细胞是病毒重新激活的永久来源,并导致HAART中断后病毒载量的反弹。因此,更深入地了解调节前病毒潜伏和重新激活的分子机制,应该会带来旨在清除这些HIV-1细胞储存库的合理策略。本综述总结了我们目前对HIV-1转录重新激活所涉及的因素的认识和理解:(1)整合位点;(2)转录因子NF-κB,它由促炎细胞因子(如TNFα)诱导,并与HIV-1启动子区域的两个κB位点结合;(3)HIV-1启动子激活后单个核小体(称为nuc-1,在潜伏条件下位于HIV-1转录起始位点的紧下游)的特异性重塑;(4)组蛋白和非组蛋白的翻译后乙酰化(在用去乙酰化酶抑制剂处理后,诱导病毒转录和nuc-1重塑);以及(5)病毒反式激活因子Tat,它通过介导招募组蛋白修饰酶和ATP依赖性染色质重塑复合物到HIV-1启动子来促进转录,这些复合物是核小体破坏和转录持续性所必需的。最后,本综述强调了旨在施用HIV-1基因表达激活剂(如HDAC抑制剂)与有效的HAART相结合的实验性疗法,以重新激活并减少/消除潜伏感染HIV-1的细胞储存库。